Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
James F. Casella, MD
Healthcare Provider Director of the Basic and Translational Research Program
Comprehensive Sickle Cell Center
and MD Hemophilia Treatment Center
The Johns Hopkins Hospital
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, Maryland, United States
Dr. James Casella is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. As the Johns Hopkins’ Rainey Professor of Pediatric Hematology, Dr. Casella is chief of the Division of Pediatric Hematology at Johns Hopkins Children’s and director of the Basic and Translational Research Program in Sickle Cell Disease, Comprehensive Sickle Cell Center and the Maryland Hemophilia Treatment Center at Johns Hopkins.
He supervises several labs investigating the cellular and molecular basis of pediatric blood-borne diseases. He is seeking to develop better treatments for sickle cell disease and the prevention of central nervous system complications of this disorder, including stroke.
A research scientist as well as a clinician, he co-directs the hematology/oncology fellowship program at Johns Hopkins Hospital and is an adjunct senior investigator (Pediatric Oncology Branch) in the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health. He is also director of the NHLBI-funded K12 in benign hematology program at Johns Hopkins that trains young clinician/investigators in benign hematology and transfusion medicine.
+myBinderRelated Content
-
Improving Sickle Cell Transitions of Care Through Health Information TechnologyINTRODUCTION: Transitions between inpati...
-
Pediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
-
Bosede Afolabi, MBChB(Ife), DM(Notts), FRCOG, FWACS, FMCOGDr. Afolabi is a gynaecologist with inte...
-
Lewis Hsu, MD, PhDDr. Lewis Hsu is a pediatric hematologis...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Augusta University Sickle Cell CenterLocated in Augusta, Georgia, Augusta Uni...
-
Carolinas Healthcare System, Levine Children’s HospitalWith the right experts and the right car...
